NO20075099L - Alkynyl-pyrrolopyrmidiner og relaterte analoger som HSP90-inhibitorer - Google Patents

Alkynyl-pyrrolopyrmidiner og relaterte analoger som HSP90-inhibitorer

Info

Publication number
NO20075099L
NO20075099L NO20075099A NO20075099A NO20075099L NO 20075099 L NO20075099 L NO 20075099L NO 20075099 A NO20075099 A NO 20075099A NO 20075099 A NO20075099 A NO 20075099A NO 20075099 L NO20075099 L NO 20075099L
Authority
NO
Norway
Prior art keywords
pyrrolopyrmidines
alkynyl
related analogues
hsp90 inhibitors
hsp90
Prior art date
Application number
NO20075099A
Other languages
English (en)
Norwegian (no)
Inventor
Srinivas Rao Kasibhatla
Marco A Biamonte
Jiandong Shi
Marcus F Boehm
Original Assignee
Conforma Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37054161&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20075099(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Conforma Therapeutics Corp filed Critical Conforma Therapeutics Corp
Publication of NO20075099L publication Critical patent/NO20075099L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20075099A 2005-03-30 2007-10-09 Alkynyl-pyrrolopyrmidiner og relaterte analoger som HSP90-inhibitorer NO20075099L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66689905P 2005-03-30 2005-03-30
PCT/US2006/011846 WO2006105372A2 (en) 2005-03-30 2006-03-29 Alkynyl pyrrolopyrimidines and related analogs as hsp90-inhibitors

Publications (1)

Publication Number Publication Date
NO20075099L true NO20075099L (no) 2007-10-29

Family

ID=37054161

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075099A NO20075099L (no) 2005-03-30 2007-10-09 Alkynyl-pyrrolopyrmidiner og relaterte analoger som HSP90-inhibitorer

Country Status (15)

Country Link
US (2) US7544672B2 (pt)
EP (1) EP1869027A4 (pt)
JP (1) JP2008534609A (pt)
KR (1) KR20080004550A (pt)
CN (1) CN101180297A (pt)
AU (1) AU2006230447A1 (pt)
BR (1) BRPI0609509A2 (pt)
CA (1) CA2602257A1 (pt)
EA (1) EA013522B1 (pt)
IL (1) IL186270A (pt)
MX (1) MX2007011903A (pt)
NO (1) NO20075099L (pt)
NZ (1) NZ561939A (pt)
WO (1) WO2006105372A2 (pt)
ZA (1) ZA200708520B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0609509A2 (pt) 2005-03-30 2010-04-13 Conforma Therapeutics Corp composto ou um polimorfo, solvato, tautÈmero, enanciÈmero, pró-droga ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso do composto, polimorfo, solvato, tautÈmero, enanciÈmero, pró-droga ou sal farmaceuticamente aceitável
CA2645343A1 (en) * 2006-03-11 2007-09-20 Vernalis (R&D) Limited Pyrrolopyrimidine derivatives used as hsp90 inhibitors
WO2007131034A1 (en) * 2006-05-03 2007-11-15 The Regents Of The University Of Michigan Pyrimidone derivatives which are modulators of heat shock protein (hsp) 70
AU2007249194B2 (en) 2006-05-12 2012-11-22 Myrexis, Inc. Therapeutic compounds and their use in cancer
WO2008045529A1 (en) * 2006-10-12 2008-04-17 Serenex, Inc. Purine and pyrimidine derivatives for treatment of cancer and inflammatory diseases
CL2007002994A1 (es) * 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
FR2907453B1 (fr) 2006-10-24 2008-12-26 Sanofi Aventis Sa Nouveaux derives du fluorene,compositions les contenant et utilisation
JP2010517989A (ja) 2007-02-01 2010-05-27 アストラゼネカ アクチボラグ Ｈｓｐ９０阻害剤としての５，６，７，８−テトラヒドロプテリジン誘導体
WO2008096218A1 (en) * 2007-02-06 2008-08-14 Pfizer Inc. 2-amin0-5, 7-dihydr0-6h- pyrrolo [3, 4-d] pyrimidine derivatives as hsp-90 inhibitors for treating cancer
WO2009030871A1 (en) * 2007-09-07 2009-03-12 Vernalis R & D Ltd Pyrrolopyrimidine derivatives having hsp90 inhibitory activity
LT5623B (lt) 2008-04-30 2010-01-25 Biotechnologijos Institutas, , 5-aril-4-(5-pakeistieji 2,4-dihidroksifenil)-1,2,3-tiadiazolai kaip hsp90 šaperono slopikliai ir tarpiniai junginiai jiems gauti
WO2010018481A1 (en) 2008-08-13 2010-02-18 Pfizer Inc. 2-amino pyrimidine compounds as potent hsp-90 inhibitors
WO2010036380A1 (en) 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors
GB0819102D0 (en) * 2008-10-17 2008-11-26 Chroma Therapeutics Ltd Pyrrolo-pyrimidine compounds
GB0819105D0 (en) * 2008-10-17 2008-11-26 Chroma Therapeutics Ltd Pyrrolo-pyrimidine compounds
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
AU2010319927B2 (en) * 2009-10-29 2015-01-22 Janssen Pharmaceutica Nv Alkynyl derivatives useful as DPP-1 inhibitors
WO2014145576A2 (en) 2013-03-15 2014-09-18 Northwestern University Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer
US9598455B2 (en) * 2014-03-30 2017-03-21 Cepheid Modified thymine polynucleotide oligomers and methods
US9598456B2 (en) * 2014-03-30 2017-03-21 Cepheid Modified cytosine polynucleotide oligomers and methods
KR102133569B1 (ko) * 2018-06-28 2020-07-13 한국과학기술연구원 신규한 피롤로[2,3-d]피리미딘-4-온 유도체 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
CN115192712B (zh) * 2022-07-05 2023-08-01 四川大学华西第二医院 Hsp抑制剂在制备胚胎神经系统畸形治疗的产品中的应用

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3595955A (en) 1969-03-26 1971-07-27 Upjohn Co Geldanamycin and process for producing same
US4261989A (en) 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
IL64501A (en) 1980-12-22 1985-07-31 Astra Laekemedel Ab 9-substituted 4-hydroxybutyl guanine derivatives,their preparation and antiviral use
US4533254A (en) 1981-04-17 1985-08-06 Biotechnology Development Corporation Apparatus for forming emulsions
US4699877A (en) 1982-11-04 1987-10-13 The Regents Of The University Of California Methods and compositions for detecting human tumors
US4806642A (en) 1984-10-05 1989-02-21 Warner-Lambert Company Purine derivatives
US5098906A (en) 1983-10-31 1992-03-24 Warner-Lambert Company Purine derivatives
US4921859A (en) 1983-10-31 1990-05-01 Warner-Lambert Company Purine derivatives
US4547573A (en) 1983-12-02 1985-10-15 Ici Pharma Process for preparing cephalosporin derivatives
DE3578499D1 (de) 1984-02-02 1990-08-09 Merck & Co Inc 5-(amino oder substituiertes amino)-1,2,3-triazole.
US4748177A (en) 1984-03-26 1988-05-31 Warner-Lambert Company Guanine derivatives
US4617304A (en) 1984-04-10 1986-10-14 Merck & Co., Inc. Purine derivatives
IT1196261B (it) 1984-09-20 1988-11-16 Pierrel Spa Derivati nucleosidici e purinici 8-sostituiti
IL76546A (en) 1984-10-12 1988-12-30 Warner Lambert Co 9-(heteroarylalkyl)-6-purine(thi)one derivatives,their preparation and pharmaceutical compositions containing them
US4772606A (en) 1985-08-22 1988-09-20 Warner-Lambert Company Purine derivatives
JO1406B1 (en) 1984-11-02 1986-11-30 سميث كلاين اند فرينش لابوراتوريز ليمتد Chemical compounds
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
JP2528107B2 (ja) 1985-03-15 1996-08-28 サマ−トン，ジエ−ムス ポリヌクレオチド測定試薬と方法
DE3512194A1 (de) 1985-04-03 1986-10-09 Hoechst Ag, 6230 Frankfurt Ein neues ansamycin-antibiotikum, ein mikrobielles verfahren zu seiner herstellung und seine verwendung als arzneimittel
GB8515934D0 (en) 1985-06-24 1985-07-24 Janssen Pharmaceutica Nv (4-piperidinomethyl and-hetero)purines
US4918162A (en) 1986-05-06 1990-04-17 The Regents Of The University Of California Assays and antibodies for N-MYC proteins
US5002950A (en) 1986-10-24 1991-03-26 Warner-Lambert Co. 7-deazaguanines as immunomodulators
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5204353A (en) 1987-04-07 1993-04-20 Ciba-Geigy Corporation 3-benzyl-3H-1,2,3-triazolo[4,5-d]pyrimidines, compositions thereof, and method of treating epilepsy therewith
SE8801729D0 (sv) 1988-05-06 1988-05-06 Astra Ab Purine derivatives for use in therapy
US4923885A (en) 1988-08-19 1990-05-08 Merck & Co., Inc. 5-amino-1-(4-naphthoylbenzyl)-1,2,3-triazole-4-carboxamides and analogs as antiproliferative agents
EP0363320A3 (de) 1988-10-06 1991-11-21 Ciba-Geigy Ag Substituierte 9H-Purine
US5332744A (en) 1989-05-30 1994-07-26 Merck & Co., Inc. Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists
DK0465297T3 (da) 1990-07-04 1996-02-19 Merrell Pharma Inc 9-Purinylphosphonsyre-derivater
GB9020931D0 (en) 1990-09-26 1990-11-07 Wellcome Found Heterocyclic compounds
DE69230349T2 (de) 1991-03-05 2000-07-27 Ajinomoto Co., Inc. Cyclopropanderivat
WO1992021032A1 (en) 1991-05-24 1992-11-26 The Regents Of The University Of California Methods for the detection of bcr-abl and abnormal abl proteins in leukemia patients
US6025126A (en) 1991-10-28 2000-02-15 Arch Development Corporation Methods and compositions for the detection of chromosomal aberrations
HU9401936D0 (en) 1992-01-06 1994-09-28 Pfizer Process and uses for 4,5-diohydrogeldanamycin and its hydroquinone
CA2093403C (en) 1992-04-08 1999-08-10 Fumio Suzuki Therapeutic agent for parkinson's disease
JPH0680670A (ja) 1992-09-03 1994-03-22 Ajinomoto Co Inc シクロプロパン誘導体及びその製造法
US6005107A (en) 1992-12-23 1999-12-21 Biochem Pharma, Inc. Antiviral compounds
US6444656B1 (en) 1992-12-23 2002-09-03 Biochem Pharma, Inc. Antiviral phosphonate nucleotides
GB9226879D0 (en) 1992-12-23 1993-02-17 Iaf Biochem Int Anti-viral compounds
US5387584A (en) 1993-04-07 1995-02-07 Pfizer Inc. Bicyclic ansamycins
US5602156A (en) 1993-09-17 1997-02-11 The United States Of America As Represented By The Department Of Health And Human Services Method for inhibiting metalloproteinase expression
US5744492A (en) 1993-09-17 1998-04-28 United States Of America Method for inhibiting angiogenesis
GB9402161D0 (en) 1994-02-04 1994-03-30 Wellcome Found Chloropyrimidine intermediates
JP3769737B2 (ja) 1994-03-30 2006-04-26 味の素株式会社 シクロプロパン誘導体及びその製造法
US5932566A (en) 1994-06-16 1999-08-03 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
US6110923A (en) 1994-06-22 2000-08-29 Biochem Pharma Inc. Method for treating cancer using novel substituted purinyl derivatives with immunomodulating activity
US5525606A (en) 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
JPH0841035A (ja) 1994-08-05 1996-02-13 Ajinomoto Co Inc シクロプロパン誘導体及びその製造法
US5846749A (en) 1994-10-12 1998-12-08 The Regents Of The University Of California Quantitative measurement of tissue protein identified by immunohistochemistry and standardized protein determination
JPH08208687A (ja) 1994-11-25 1996-08-13 Sankyo Co Ltd グリセリルオリゴヌクレオチド
US5656629A (en) 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
US6177460B1 (en) 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
JPH0920776A (ja) 1995-06-30 1997-01-21 Nippon Paper Ind Co Ltd 新規なプリンヌクレオシド誘導体、その製造方法及びその誘導体を有効成分とする抗ウイルス剤
JPH09169758A (ja) 1995-10-18 1997-06-30 Nippon Paper Ind Co Ltd 新規なプリンヌクレオシド誘導体、その製造方法、及びそれを用いた抗ウイルス剤
JPH1025294A (ja) 1996-03-26 1998-01-27 Akira Matsuda 縮合ヘテロ環誘導体、その製造法及びそれを含有する悪性腫瘍治療剤
JP4667543B2 (ja) 1996-07-03 2011-04-13 大日本住友製薬株式会社 新規プリン誘導体
US6723727B1 (en) 1996-12-20 2004-04-20 Hoechst Aktiengesellschaft Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them
WO1998039344A1 (en) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
US5861503A (en) 1997-04-30 1999-01-19 The Regents Of The University Of California Process for producing 8-fluoropurines
ATE460423T1 (de) 1997-05-14 2010-03-15 Sloan Kettering Inst Cancer Verfahren und zubereitungen zur zerstörung bestimmter proteine
JP2002507996A (ja) 1997-07-03 2002-03-12 デュポン ファーマシューティカルズ カンパニー 神経学的障害を治療するためのイミダゾピリミジン類およびイミダゾピリジン類
EP1017394B1 (en) 1997-07-12 2005-12-07 Cancer Research Technology Limited Cyclin dependent kinase inhibiting purine derivatives
AUPO912997A0 (en) 1997-09-11 1997-10-02 Commonwealth Scientific And Industrial Research Organisation Antiviral agents
WO1999016465A1 (en) 1997-09-30 1999-04-08 Beth Israel Deaconess Medical Center Method for inhibiting tumor angiogenesis in a living subject
US5968921A (en) 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
DE69824632T2 (de) 1997-11-12 2005-06-09 Mitsubishi Chemical Corp. Purinderivate und medikamente, welche dieselben als aktiven bestandteil enthalten
TW572758B (en) 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
WO1999051223A1 (en) 1998-04-03 1999-10-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
SI20022A (sl) 1998-07-29 2000-02-29 Kemijski inštitut Alkilno substituirani purinovi derivati in njihova priprava
JP2000072773A (ja) 1998-08-28 2000-03-07 Zeria Pharmaceut Co Ltd プリン誘導体
JP2000072733A (ja) 1998-08-31 2000-03-07 Kanebo Ltd アミド化合物の製造法
US6140374A (en) 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
CA2356959C (en) 1998-12-22 2009-03-31 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Water-insoluble drug delivery system
US7122635B2 (en) 1999-01-06 2006-10-17 University Of Southern California Method and composition for angiogenesis inhibition
IL144675A0 (en) 1999-02-01 2002-05-23 Cv Therapeutics Inc PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkB-α
FR2790702B1 (fr) 1999-03-08 2001-07-20 Sidel Sa Unite de moulage et machine d'extrusion-soufflage munie d'une telle unite
US6174875B1 (en) 1999-04-01 2001-01-16 University Of Pittsburgh Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
AU769235B2 (en) 1999-04-09 2004-01-22 Sloan-Kettering Institute For Cancer Research Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases
AU4589800A (en) 1999-05-05 2000-11-21 Darwin Discovery Limited 9-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,9-dihydropurin-6-one derivatives as pde7inhibitors
US6660845B1 (en) 1999-11-23 2003-12-09 Epoch Biosciences, Inc. Non-aggregating, non-quenching oligomers comprising nucleotide analogues; methods of synthesis and use thereof
US20030187261A1 (en) 2000-01-07 2003-10-02 Libor Havlicek Purine derivatives, process for their preparation and use thereof
WO2001072779A1 (en) 2000-03-24 2001-10-04 Duke University Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
DE60144277D1 (de) 2000-04-25 2011-05-05 Icos Corp Hemmer der menschlichen phosphatidyl-inositol-3-kinase delta
US6887853B2 (en) 2000-06-29 2005-05-03 The Trustees Of Boston University Use of geldanamycin and related compounds for treatment of fibrogenic disorders
US6946456B2 (en) 2000-07-28 2005-09-20 Sloan-Kettering Institute For Cancer Research Methods for treating cell proliferative disorders and viral infections
US7439359B2 (en) 2000-11-02 2008-10-21 Sloan-Kettering Institute For Cancer Research Small molecule compositions for binding to hsp90
JP2004512381A (ja) 2000-11-02 2004-04-22 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ Ｈｓｐ９０インヒビターの使用により細胞毒性剤の効力を増強させる方法
GB0100621D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VI
GB0100623D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
GB0100624D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
MY141789A (en) 2001-01-19 2010-06-30 Lg Chem Investment Ltd Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same.
CA2440809A1 (en) 2001-03-01 2002-09-12 Conforma Therapeutics Corp. Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors
JP4331944B2 (ja) 2001-04-17 2009-09-16 大日本住友製薬株式会社 新規アデニン誘導体
US20020156277A1 (en) 2001-04-20 2002-10-24 Fick David B. Synthesis and methods of use of purine analogues and derivatives
US20030022864A1 (en) 2001-04-24 2003-01-30 Ishaq Khalid S. 9-[(5-dihydroxyboryl)-pentyl] purines, useful as an inhibitor of inflammatory cytokines
WO2002088079A2 (en) 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
US7825094B2 (en) 2001-05-23 2010-11-02 Sloan-Kettering Institute For Cancer Research Method of treatment for cancers associated with elevated HER 2 levels
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
WO2003000200A2 (en) 2001-06-22 2003-01-03 Pharmasset Ltd. β-2'-OR 3'-HALONUCLEOSIDES
EP1399446B1 (en) 2001-06-27 2005-08-03 Cyclacel Limited 2,6,9-substituted purine derivatives and their use in the treatment of proliferative disorders
US6962991B2 (en) 2001-09-12 2005-11-08 Epoch Biosciences, Inc. Process for the synthesis of pyrazolopyrimidines
JP2005504086A (ja) 2001-09-24 2005-02-10 コンフォーマ セラピューティクス コーポレーション １７−アリルアミノゲルダナマイシン（１７−ａａｇ）および他のアンサマイシン類を製造する方法
JP2003113181A (ja) 2001-10-04 2003-04-18 Sumika Fine Chemicals Co Ltd ６−ハロプリンの製造方法
DE10152275A1 (de) 2001-10-23 2003-04-30 Bayer Ag Verfahren zur Elektrolyse von wässrigen Lösungen aus Chlorwasserstoff
EP1440072A4 (en) 2001-10-30 2005-02-02 Conforma Therapeutic Corp PURINE ANALOGS HAVING HSP90 INHIBITORY ACTIVITY
EP1472335A4 (en) 2001-11-08 2005-12-28 Univ Johns Hopkins METHODS AND SYSTEMS FOR SEQUENCING NUCLEIC ACIDS
WO2003041643A2 (en) 2001-11-09 2003-05-22 Conforma Therapeutics Corporation Hsp90-inhibiting zearalanol compounds and methods of producing and using same
EP1519735A4 (en) 2001-12-12 2006-01-11 Conforma Therapeutic Corp ASSAYS AND DEVICES FOR DETERMINING AND MODULATING HSP90 BINDING ACTIVITY
US7465718B2 (en) 2002-02-08 2008-12-16 Conforma Therapeutics Corporation Ansamycins having improved pharmacological and biological properties
TW200303363A (en) 2002-02-25 2003-09-01 Upjohn Co Process to prepare and isolate geldanamycin
WO2003086381A1 (en) 2002-04-10 2003-10-23 Conforma Therapeutics Corporation Ansamycin formulations and methods for producing and using same
JP2004018453A (ja) 2002-06-14 2004-01-22 Sumika Fine Chemicals Co Ltd アルキニルプリン化合物およびその製造方法
US7332486B2 (en) 2002-08-08 2008-02-19 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
GB0219746D0 (en) 2002-08-23 2002-10-02 Inst Of Ex Botany Ascr Azapurine derivatives
WO2004024082A2 (en) 2002-09-13 2004-03-25 Irm, Llc Highly specific modulators of gtpases for target validation
EP1546164A4 (en) 2002-09-26 2006-06-07 Lg Life Sciences Ltd (+) - TRANS-ISOMERS OF (1-PHOSPHONOMETHOXY-2-ALKYLCYCLOPROPYL) METHYL NUCLEOSIDE DERIVATIVES, METHOD FOR THE PRODUCTION OF STEREO-ISOMERS THEREOF, AND THE USE OF ANTIVIRAL AGENTS PRODUCED THEREOF
US7601694B2 (en) 2003-02-20 2009-10-13 New York University CLK-peptide and SLK-peptide
US20060252729A1 (en) 2003-07-30 2006-11-09 Krawczyk Steven H Nucleobase phosphonate analogs for antiviral treatment
US20050043239A1 (en) 2003-08-14 2005-02-24 Jason Douangpanya Methods of inhibiting immune responses stimulated by an endogenous factor
US20050054614A1 (en) 2003-08-14 2005-03-10 Diacovo Thomas G. Methods of inhibiting leukocyte accumulation
ES2559779T3 (es) * 2003-08-29 2016-02-15 Vernalis (R&D) Limited Compuestos de pirimidotiofeno
NZ546611A (en) 2003-09-18 2010-02-26 Conforma Therapeutics Corp Novel heterocyclic compounds as HSP90-inhibitors
ES2361835T3 (es) 2003-09-25 2011-06-22 Janssen Pharmaceutica Nv Derivados de purina inhibidores de la replicación del hiv.
KR20050062940A (ko) 2003-12-19 2005-06-28 주식회사 엘지생명과학 디이소프로필((1-((2-아미노-6-할로-9ｈ-퓨린-9-일)메틸)사이클로프로필)옥시)-메틸포스포네이트의 새로운 제조방법
KR20050062944A (ko) 2003-12-19 2005-06-28 주식회사 엘지생명과학 디이소프로필((1-((2-아미노-6-클로로-9ｈ-퓨린-9-일)메틸)사이클로프로필)옥시)-메틸포스포네이트의 새로운 제조방법
CA2552664A1 (en) 2004-01-08 2005-07-28 Michigan State University Methods for treating and preventing hypertension and hypertension-related disorders
TW200533358A (en) 2004-02-17 2005-10-16 Anadys Pharmaceuticals Inc Nucleoside phosphonate derivatives useful in the treatment of hiv infections
JP2007526282A (ja) 2004-03-02 2007-09-13 ウペエフエル・エコル・ポリテクニック・フェデラル・ドゥ・ローザンヌ Ｏ６−アルキルグアニンｄｎａアルキルトランスフェラーゼ特異的基質
WO2005092892A1 (ja) 2004-03-26 2005-10-06 Dainippon Sumitomo Pharma Co., Ltd. ８−オキソアデニン化合物
BRPI0609509A2 (pt) 2005-03-30 2010-04-13 Conforma Therapeutics Corp composto ou um polimorfo, solvato, tautÈmero, enanciÈmero, pró-droga ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso do composto, polimorfo, solvato, tautÈmero, enanciÈmero, pró-droga ou sal farmaceuticamente aceitável

Also Published As

Publication number Publication date
IL186270A0 (en) 2008-01-20
EA200702109A1 (ru) 2008-06-30
WO2006105372A3 (en) 2007-07-19
US20090318387A1 (en) 2009-12-24
ZA200708520B (en) 2008-10-29
US7544672B2 (en) 2009-06-09
KR20080004550A (ko) 2008-01-09
IL186270A (en) 2012-08-30
EA013522B1 (ru) 2010-06-30
JP2008534609A (ja) 2008-08-28
CN101180297A (zh) 2008-05-14
US20060223797A1 (en) 2006-10-05
EP1869027A2 (en) 2007-12-26
MX2007011903A (es) 2007-12-05
AU2006230447A1 (en) 2006-10-05
NZ561939A (en) 2011-03-31
BRPI0609509A2 (pt) 2010-04-13
WO2006105372A2 (en) 2006-10-05
CA2602257A1 (en) 2006-10-05
US8093229B2 (en) 2012-01-10
EP1869027A4 (en) 2010-06-23

Similar Documents

Publication Publication Date Title
NO20073140L (no) Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser
NO20082508L (no) Aminopyrimidiner anvendelige som kinaseinhibitorer
TW200514776A (en) Aminotriazole compounds useful as inhibitors of protein kinases
WO2004046120A3 (en) Diaminotriazoles useful as inhibitors of protein kinases
NO20082026L (no) Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
NO20052595L (no) Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser.
EP1485381B8 (en) Azolylaminoazine as inhibitors of protein kinases
IL184898A0 (en) Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same
NO20073628L (no) Pyridoner som er nyttige som inhibitorer av kinaser
TW200604168A (en) Azaindoles useful as inhibitors of rock and other protein kinases
NO20072567L (no) Triazoler nyttige som proteinkinase-inhibitorer
NO20053470L (no) Triazolopyridaziner som proteinkinase-inhibitorer
NO20084435L (no) C-MET proteinkinaseinhibitorer
DE60332604D1 (de) Azolylaminoazine als proteinkinasehemmer
WO2005028475A3 (en) Compositions useful as inhibitors of protein kinases
AU2003220299A1 (en) Azinylaminoazoles as inhibitors of protein kinases
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
MX2007014619A (es) Pirrolopiridinas de utilidad como inhibidores de proteina quinasa.
WO2005105780A3 (en) Compositions useful as inhibitors of rock and other protein kinases
IL200793A0 (en) Aminopyrimidines, compositions comprising the same and use thereof for inhibiting protein kinases
WO2005019190A3 (en) (4 -amino -1,2, 5-oxadiazol-4-yl) -hetξroaromatic compounds useful as protein kinase inhibitors
NO20065727L (no) Pyrrolinhibitorer av erk-proteinkinase, syntese derav og deres mellomprodukter
NO20076515L (no) Hydantoinforbindelser
NO20070502L (no) Azaindoler nyttige som inhibitorer av proteinkinaser
EA200702109A1 (ru) Алкинилпирролопиримидины и их применение в качестве ингибиторов hsp90

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application